Search
LX201
go.drugbank.com/drugs/DB04943InvestigationalIt is being developed by Lux Biosciences, Inc. … LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year.
BI-K0376
go.drugbank.com/drugs/DB05858ExperimentalIt is under investigation by Pfizer and has gone through phase I of the clinical trails.
Panobacumab
go.drugbank.com/drugs/DB15342InvestigationalPanobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).
Lenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalLenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth … However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.
Zolazepam
go.drugbank.com/drugs/DB11555ExperimentalVet approvedIt is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.
RI 624
go.drugbank.com/drugs/DB05892ExperimentalRI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Selenium Sulfide
go.drugbank.com/drugs/DB00971ApprovedSelenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea. Selenium Sulfide is the active ingredient often used in shampoos for the treatment of dandruff, seborrhei...
Products: Selsun Blue Normal to OilyPIK3CA
go.drugbank.com/drugs/DB14954InvestigationalPIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).
Hypoxanthine
go.drugbank.com/drugs/DB04076InvestigationalHypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.
LY3884961
go.drugbank.com/drugs/DB17070InvestigationalLY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]